Clinical trial · Interventional
A Study of Apatinib Treatment in for Advanced Ovarian Cancer
A Study of Apatinib in Combination With Chemotherapy Versus Chemotherapy Alone for Advanced Ovarian Cancer
NCT03393507CI-TRIAL-00031184unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is evaluated the effacy and safety of apatinib combined with chemotherapy in the advanced ovarian cancer
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapeutic Toxicity | — | UNRESOLVED | — |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Apatinib | Drug | — | UNRESOLVED |
| Taxus + platinum | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- apatinib combine with chemotherapy
- interventionNames
- Drug: Apatinib
- Drug: Taxus + platinum
- type
- ACTIVE_COMPARATOR
- label
- chemotherapy
- interventionNames
- Drug: Taxus + platinum
Primary outcomes (2)
- measure
- PFS(Progress free survival)
- timeFrame
- 24 month
- description
- he length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically diagnosed as epithelial ovarian cancer, fallopian tube cancer, stage II-IV period, the expected survival of\> 6 months; * ECOG \<2; * Liver and kidney function is normal; * No uncontrollable high blood pressure, bleeding, perforation, obstruction. Exclusion Criteria: * Serious cardiopulmonary insufficiency, can not tolerate chemotherapy; * Pregnant or lactating women; * 3 years have occurred in other tumors (cervical cancer in situ, has cured basal cell carcinoma, except for bladder epithelial tumors); * Allergic to apatinib or its accessories.
References
Publications (0)
Data not yet available
No reference posted for this study.